BMS-986504 + Olaparib for Cancer

This trial explores the safety and effects of a new treatment combining BMS-986504 (an experimental treatment) and olaparib for individuals with advanced solid tumors lacking a specific protein called MTAP. The study includes different parts to test the treatments in unique ways, with some groups starting both drugs together and others taking them at different times. It suits those with advanced or metastatic cancers, such as pancreatic or bile duct cancer, who have no other treatment options. Participants should have tumors that lack the MTAP protein. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial requires a washout period (time without taking certain medications) from prior therapies, including 3 weeks from any treatment for systemic tumor control and 5 half-lives from small molecule targeted agents. Additionally, you cannot use strong CYP3A inhibitors or inducers within 14 days before starting the study and during the study period.

Research has shown that the combination of BMS-986504 and olaparib is being tested for safety in people with advanced solid tumors. Previous studies have examined how well patients tolerate this treatment pair. Some side effects have been reported and graded to help doctors assess their severity.

Researchers are excited about the combination of BMS-986504 and Olaparib for cancer treatment because of its unique dual-action approach. Traditional cancer treatments often focus on single pathways, but BMS-986504 targets specific cancer cell mechanisms, potentially enhancing the effectiveness of Olaparib, a PARP inhibitor that already disrupts cancer cell DNA repair. This combination could lead to more effective tumor suppression and improved outcomes for patients, offering a new hope beyond current standard options like chemotherapy and radiation.

Research has shown that olaparib can effectively treat certain cancers, such as pancreatic cancer, especially when specific genetic changes (BRCA1/2) are present. In the POLO study, it helped patients live longer without disease progression. Additionally, when combined with chemotherapy, olaparib can enhance treatment effectiveness and extend survival in people with advanced triple-negative breast cancer. This trial examines BMS-986504 in combination with olaparib to assess its efficacy, particularly in advanced solid tumors with a genetic feature called MTAP loss. Although limited data exists on this combination, ongoing research is evaluating its safety and potential benefits.¹²⁴⁶⁷